Phenylalanine

Phenylalanine (abbreviated Phe or F; IUPAC name (2*S*)-2-amino-3-phenylpropanoic acid; molecular formula C₉H₁₁NO₂; molecular mass 165.19 Da) is an essential, nonpolar, aromatic proteinogenic α-amino acid encoded by the genetic code codons UUU and UUC. Historically, a synthetic polyuridylic acid (poly-U) RNA homopolymer directing cell-free synthesis of polyphenylalanine enabled Marshall Nirenberg and J. Heinrich Matthaei in 1961 to crack the first codon of the genetic code (UUU = Phe). First isolated in 1879 by Ernst Schulze and Julius Barbieri from yellow lupine (Lupinus luteus) seedlings and chemically synthesized in 1882 by Emil Erlenmeyer and Friedrich Lipp, phenylalanine consists of an alanine backbone substituted at the β-carbon with a hydrophobic phenyl ring (forming a benzyl side chain, –CH₂–C₆H₅).

Lacking any ionizable or hydrogen-bonding heteroatoms on its six-membered benzene ring (α-COOH pK_a1 = 1.83, α-NH₃⁺ pK_a2 = 9.13, isoelectric point pI = 5.48), phenylalanine is the most hydrophobic of the three aromatic amino acids, registering a Kyte-Doolittle hydropathy index of +2.8 (surpassed only by isoleucine, valine, and leucine). Within folded protein domains, phenylalanine side chains pack inside solvent-excluded hydrophobic cores and mediate directional aromatic π–π stacking and cation–π interactions. Because mammals lack the microbial and plant shikimate–chorismate–prephenate pathway, humans must obtain L-phenylalanine from dietary protein; in the liver, excess phenylalanine is hydroxylated to tyrosine by phenylalanine hydroxylase (PAH), an enzyme whose autosomal recessive deficiency causes phenylketonuria (PKU), the most common inborn error of amino-acid metabolism.

Hydrophobic Core Packing, Quadrupole π–π Stacking, and Cation–π Interactions

Although the phenyl ring of phenylalanine has no net charge or permanent dipole moment, the higher electronegativity of sp²-hybridized ring carbons relative to hydrogens—combined with the delocalized 6-π-electron clouds above and below the ring plane—creates a strong electrostatic quadrupole moment (Θ_zz ≈ −29 × 10⁻⁴⁰ C·m²), with partial negative electrostatic potential (δ⁻) on both π-faces of the ring and a belt of partial positive electrostatic potential (δ⁺) around the peripheral C–H ring edge. This quadrupolar charge distribution governs two non-covalent interactions in structural biology and molecular docking:

1. Aromatic π–π Stacking Geometries: When two phenylalanine rings (or Phe paired with tyrosine, tryptophan, or histidine) pack within 4.5 to 7.0 Å of each other inside a protein core, direct face-to-face eclipsing is electrostatically repulsive because the two δ⁻ π-clouds repel. Instead, high-resolution crystal structures reveal two energetically favorable orientations (stabilized by ~1.5 to 3.0 kcal/mol per pair):

• T-Shaped (Edge-to-Face) Geometry: The positively polarized δ⁺ C–H edge of one phenyl ring points nearly perpendicularly (dihedral angle 60°–90°, centroid distance ~5.0 Å) into the negatively polarized δ⁻ π-face of its partner.
• Parallel-Displaced (Offset Stacked) Geometry: The two rings lie parallel (inter-planar spacing ~3.4–3.8 Å) but are laterally offset by ~1.5–2.0 Å so that the δ⁺ ring edge of one overlaps the δ⁻ π-center of the other.

1. Cation–π and CH–π Interactions: The electron-rich π-face of phenylalanine binds positively charged side chains—specifically the guanidinium group of arginine and the ε-ammonium group of lysine (as well as quaternary ammonium ligands such as acetylcholine)—providing 2 to 5 kcal/mol of electrostatic and induction stabilization even in solvent-exposed binding pockets. Conversely, in pathogenic short peptides such as the Alzheimer's amyloid-β (Aβ) central hydrophobic core (KLVFF, residues 16–20) or islet amyloid polypeptide, intermolecular Phe–Phe π-stacking accelerates cross-β fibril nucleation. Spectroscopically, phenylalanine exhibits a weak benzenoid π → π* ultraviolet absorption band centered at λ_max = 257.5 nm with a low molar extinction coefficient (ε₂₅₇ ≈ 195 M⁻¹ cm⁻¹, and virtually zero absorbance at 280 nm) and faint fluorescence emission at 282 nm.

The Shikimate, Chorismate, and Prephenate Biosynthetic Pathway

In bacteria, archaea, fungi, and plastids of higher plants, phenylalanine is synthesized from the glycolytic intermediate phosphoenolpyruvate (PEP) and the pentose-phosphate pathway intermediate erythrose-4-phosphate (E4P) via the seven-step shikimate pathway leading to the common branch-point intermediate chorismate:

1. Claisen Rearrangement to Prephenate: At the chorismate branch point (where anthranilate synthase diverts flux toward tryptophan), the homodimeric enzyme chorismate mutase catalyzes a pericyclic [3,3]-sigmatropic Claisen rearrangement of chorismate—accelerating the reaction ~2 × 10⁶-fold via a chair-like transition state—to form prephenate.
2. Dehydration-Decarboxylation and Transamination: In Escherichia coli and most microbes (prephenate pathway), the bifunctional enzyme chorismate mutase / prephenate dehydratase (PheA) catalyzes a concerted decarboxylative 1,4-dehydration of prephenate (releasing CO₂ and H₂O and restoring full benzene ring aromaticity) to form phenylpyruvate, which is transaminated with L-glutamate by aromatic-amino-acid aminotransferase (TyrB) to yield L-phenylalanine.
3. The Plant Arogenate Pathway and Phenylpropanoid Secondary Metabolism: In higher plants, prephenate is transaminated first by prephenate aminotransferase to form L-arogenate, which arogenate dehydratase (ADT) then decarboxylates and dehydrates to L-phenylalanine. In vascular plants, up to 30% to 40% of all photosynthetically fixed organic carbon flows through L-phenylalanine: the enzyme phenylalanine ammonia-lyase (PAL) catalyzes the non-oxidative elimination of NH₃ from phenylalanine to generate trans-cinnamate, initiating the phenylpropanoid pathway that synthesizes lignin (the structural biopolymer of wood and xylem vessels), flavonoids, anthocyanins, coumarins, and salicylic acid.

Tetrahydrobiopterin (BH₄)-Dependent Phenylalanine Hydroxylase and the NIH Shift

In mammals, roughly 75% of ingested L-phenylalanine not incorporated into new protein is catabolized in the liver (and kidney) by conversion into tyrosine, which then degrades through homogentisate into the glucogenic TCA intermediate fumarate and the ketogenic product acetoacetate. The first, irreversible, rate-limiting step is catalyzed by homotetrameric phenylalanine hydroxylase (PAH; EC 1.14.16.1), a mononuclear non-heme Fe²⁺-dependent aromatic amino-acid monooxygenase (homologous to tyrosine hydroxylase and tryptophan hydroxylase) that requires the pteridine cofactor (6*R*)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH₄) and molecular dioxygen (O₂):

L-Phenylalanine + BH₄ + O₂ → L-Tyrosine + 4a-Hydroxytetrahydrobiopterin (pterin-4a-carbinolamine)

During catalysis, O₂ reacts with the active-site Fe²⁺ center (coordinated by two histidine residues, His285 and His290, and one glutamate, Glu330) and the C4a position of BH₄ to form a bridging Fe^II–OO–BH₄ peroxypterin intermediate. Heterolytic O–O bond cleavage yields 4a-hydroxytetrahydrobiopterin and a high-valent Fe^IV=O (ferryl-oxo) species, which attacks the C4 (para) carbon of the phenylalanine ring to form a cationic arena-oxide / σ-complex intermediate. In a classic intramolecular rearrangement discovered at the National Institutes of Health and termed the NIH shift, the hydrogen atom originally attached to C4 migrates via a 1,2-hydride shift to the adjacent C3 (meta) carbon as the ring rearomatizes to form L-tyrosine.

To sustain catalytic turnover, 4a-hydroxytetrahydrobiopterin is dehydrated by pterin-4a-carbinolamine dehydratase (PCD) to quinonoid dihydrobiopterin (qBH₂), which is reduced back to active BH₄ by NADH-dependent dihydropteridine reductase (DHPR / QDPR). Furthermore, PAH exhibits positive homotropic allosteric cooperativity: binding of excess L-phenylalanine to a regulatory ACT domain on each subunit induces a large domain rotation that uncovers the active site and stimulates enzyme activity when dietary phenylalanine rises after a protein meal.

Phenylketonuria (PKU), LAT1 Blood-Brain Barrier Competition, and Aspartame Toxicity

Phenylketonuria (PKU; OMIM 261600), first described in 1934 by the Norwegian physician and chemist Ivar Asbjørn Følling and present in ~1 in 10,000 to 15,000 live births worldwide, is an autosomal recessive disorder caused in ~98% of cases by biallelic loss-of-function mutations in the PAH gene on chromosome 12q23.2 (over 1,000 cataloged variants, such as R408W) and in ~1%–2% of cases ("malignant" or atypical PKU) by defects in BH₄ biosynthesis (GCH1, PTS) or recycling (QDPR, PCBD1). When hepatic PAH activity is absent or severely reduced (< 1% in classic PKU), plasma L-phenylalanine rises from its normal physiological concentration of 50–110 μM to > 1,200–2,400 μM.

Blocked from entering tyrosine catabolism, accumulated phenylalanine undergoes minor transamination to the α-ketoacid phenylpyruvate (a phenylketone) and its derivatives phenyllactate, phenylacetate (which conjugates with glutamine to form phenylacetylglutamine, imparting a characteristic "musty" or "mousy" odor to urine and sweat), and ortho-hydroxyphenylacetate. If untreated from infancy, classic PKU causes severe, irreversible intellectual disability, microcephaly, hypomyelination, seizures, and hypopigmentation of skin, hair, and irides (because high phenylalanine competitively inhibits tyrosinase, the rate-limiting enzyme of melanin synthesis from tyrosine).

The primary mechanism of PKU neurotoxicity at the blood-brain barrier involves the large neutral amino-acid transporter 1 (LAT1 / SLC7A5):

• LAT1 is the shared, saturable carrier that transports all large neutral amino acids—phenylalanine, tyrosine, tryptophan, leucine, isoleucine, valine, methionine, and histidine—into the central nervous system, and it exhibits its highest binding affinity (lowest K_m ≈ 10–20 μM) specifically for L-phenylalanine.
• When plasma phenylalanine exceeds 600–1,200 μM, phenylalanine completely saturates LAT1 and competitively blocks the entry of tyrosine and tryptophan into the brain, starving cerebral neurons of the precursors required to synthesize dopamine, norepinephrine, and serotonin while arresting cerebral myelin protein synthesis.

Because early neonatal intervention prevents neurological injury completely, every newborn in developed healthcare systems undergoes heel-stick blood screening (Guthrie bacterial inhibition assay or tandem mass spectrometry, MS/MS measuring the Phe/Tyr molar ratio > 3.0) at 24–72 hours of life. Clinical management combines a lifelong phenylalanine-restricted, tyrosine-supplemented medical diet, strict avoidance of the artificial dipeptide sweetener aspartame (L-aspartyl-L-phenylalanine methyl ester, which hydrolyzes in the gut into 50% L-phenylalanine by weight, along with aspartate and methanol), pharmacological chaperone therapy with sapropterin dihydrochloride (synthetic BH₄, which stabilizes misfolded PAH mutants with residual activity), and enzyme substitution therapy with pegvaliase (PEGylated recombinant Anabaena variabilis phenylalanine ammonia-lyase, which converts circulating Phe directly into harmless trans-cinnamate and trace NH₃ without requiring BH₄).

Why does phenylketonuria (PKU) make tyrosine a dietary essential amino acid and cause fair skin and hair?

In healthy individuals, tyrosine is nutritionally non-essential because hepatic phenylalanine hydroxylase (PAH) synthesizes it continuously from dietary phenylalanine. In patients with classic PKU, PAH is inactive, so all endogenous tyrosine synthesis is abolished and tyrosine must be supplied directly in the diet. Simultaneously, millimolar circulating phenylalanine acts as a competitive inhibitor of melanocyte tyrosinase, reducing conversion of tyrosine to DOPAquinone and eumelanin and causing pale skin, blond hair, and blue irides.

Why do food and beverage labels carry a mandatory warning: "Phenylketonurics: Contains Phenylalanine"?

The artificial high-intensity sweetener aspartame (E951, ~200 times sweeter than sucrose) is the methyl ester of the dipeptide L-aspartate–L-phenylalanine. Upon ingestion, intestinal esterases and peptidases cleave aspartame quantitatively into methanol (~10% by weight), L-aspartate (~40%), and L-phenylalanine (~50%). A single 355-mL diet soda sweetened with 180 mg of aspartame releases ~90 mg of free L-phenylalanine—enough to spike blood phenylalanine levels into the neurotoxic range in an individual with PKU.

How does BH₄-deficient "atypical PKU" differ clinically from classic PAH-deficient PKU?

Roughly 1%–2% of hyperphenylalaninemia cases result from mutations in enzymes that synthesize or recycle the tetrahydrobiopterin (BH₄) cofactor (GCH1, PTS, QDPR). Because BH₄ is also the obligatory cofactor for tyrosine hydroxylase (which synthesizes L-DOPA, dopamine, and norepinephrine) and tryptophan hydroxylase (which synthesizes 5-HTP and serotonin), dietary phenylalanine restriction alone lowers blood Phe in BH₄-deficient patients but fails to prevent progressive catecholamine and serotonin depletion; these patients require direct supplementation with BH₄ (sapropterin), L-DOPA/carbidopa, and 5-hydroxytryptophan.

1. Følling, A. (1934). "Über Ausscheidung von Phenylbrenztraubensäure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillität." Hoppe-Seyler's Zeitschrift für Physiologische Chemie, 227(1–4), 169–176. https://doi.org/10.1515/bchm2.1934.227.1-4.169
2. Burley, S. K., & Petsko, G. A. (1985). "Aromatic-aromatic interaction: A mechanism of protein structure stabilization." Science, 229(4708), 23–28. https://doi.org/10.1126/science.3892686
3. Erlandsen, H., Fusetti, F., Martinez, A., Hough, E., Flatmark, T., & Stevens, R. C. (1997). "Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria." Nature Structural Biology, 4(12), 995–1000. https://doi.org/10.1038/nsb1297-995
4. Blau, N., van Spronsen, F. J., & Levy, H. L. (2010). "Phenylketonuria." The Lancet, 376(9750), 1417–1427. https://doi.org/10.1016/S0140-6736(10)60961-060961-0)